Position of vedolizumab in the current treatment of Crohn’s disease

Česká verzia

Authors: Drastich P.
Authors place of work: Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha
Published in the journal: Gastroent Hepatol 2020; 74(2): 148-153
Category:
doi: https://doi.org/10.14735/amgh2020148

Summary

Vedolizumab (VDZ) is a gut-selective anti-integrin monoclonal antibody indicated for the treatment of patients with moderate and severe Crohn’s disease, who have failed conventional or anti-tumour necrosis factor α therapies. The main objectives in Crohn’s disease are to avoid disease complications and preserve the patient’s quality of life. Clinical trials and real-life data have shown that VDZ is effective and safe for the treatment of Crohn’s disease patients. The objective of this article is to present new data and answer practical questions regarding the role of VDZ in the therapy of Crohn’s disease.

Keywords:

vedolizumab – Crohn’s disease – anti-integrin therapy

Zdroje

1. Torres J, Mehandru S, Colombel JF et al. Crohn’s disease. Lancet 2017; 389(10080): 1741–1755. doi: 10.1016/S0140-6736(16)31711-1.

2. Gomollón F, Dignass A, Annese V et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 2017; 11(1): 3–25. doi: 10.1093/ecco-jcc/jjw168.

3. Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn’s disease management. United European Gastroenterol J 2020; 8(2): 133–139. doi: 10.1177/2050640619887316.

4. Lukáš M. Vedolizumab v léčbě Crohnovy choroby. Gastroent Hepatol 2015; 69(2):146–150. doi: 10.14735/amgh2015146.

5. Danese S, Sandborn WJ, Colombel JF et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology 2019; 157(4): 1007–1018. doi: 10.1053/j.gastro.2019.06.038.

6. Löwenberg M, Vermeire S, Mostafavi N et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s disease. Gastroenterology 2019; 157(4): 997–1006. doi: 10.1053/j.gastro.2019.05.067.

7. Faleck DM, Winters A, Chablaney S et al. Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn’s disease but not ulcerative colitis. Clin Gastroenterol Hepatol 2019; 17(12): 2497–2505. doi: 10.1016/j.cgh.2018.12.040.

8. Feagan BG, Lasch K, Lissoos T et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019; 17(1): 130–138. doi: 10.1016/j.cgh.2018.05.026.

9. Ungaro RC, Yarur A, Jossen J et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J Crohns Colitis 2019; 13(8): 963–969. doi: 10.1093/ecco-jcc/jjz041.

10. Williet N, Boschetti G, Fovet M et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol 2017; 15(11): 1750–1757. doi: 10.1016/j.cgh.2016.11.023.

11. Yacoub W, Williet N, Pouillon L et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther 2018; 47(7): 906–912. doi: 10.1111/apt.14548.

12. Dulai PS, Boland BS, Singh S et al. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease. Gastroenterology 2018; 155(3): 687–695. doi: 10.1053/j.gastro.2018.05.039.

13. Bressler B. Use of vedolizumab for the treatment of Crohn’s disease. Gastroenterol Hepatol (NY) 2019; 15(4): 204–206.

14. Samaan MA, Birdi S, Morales MA et al. Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. Frontline Gastroenterology 2019; 11(3): 177. doi: 10.1136/flgastro-2020-101467.

15. Peyrin-Biroulet L, Danese S, Argollo M et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019; 17(5): 838–846. doi: 10.1016/j.cgh.2018.06.026.

16. Lightner AL, McKenna NP, Tse CS et al. Postoperative outcomes in vedolizumab-treated Crohn’s disease patients undergoing major abdominal operations. Aliment Pharmacol Ther 2018; 47(5): 573–580. doi: 10.1111/apt.14459.

17. Lightner AL, McKenna NP, Alsughayer A et al. Biologics and 30-day postoperative complications after abdominal operations for Crohn’s disease: are there differences in the safety profiles? Dis Colon Rectum 2019; 62(11): 1352–1362. doi: 10.1097/DCR.0000000000001482.

18. Novello M, Stocchi L, Steele SR et al. Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs other biologics. J Crohns Colitis 2020; 14(2): 185–191. doi: 10.1093/ecco-jcc/jjz129.

19. Kotze PG, Ma C, Mckenna N et al. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. Therap Adv Gastroenterol 2018; 11: 1756284818783614. doi: 10.1177/1756284818783614.

20. Lee MJ, Parker CE, Taylor SR et al. Efficacy of medical therapies for fistulizing Crohn’s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018; 16(12): 1879–1892. doi: 10.1016/j.cgh.2018.01.030.

21. Feagan BG, Schwartz D, Danese S et al. Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis 2018; 12(5): 621–626. doi: 10.1093/ecco-jcc/jjy019.

22. Chapuis-Biron C, Bourrier A, Nachury M et al. Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther 2020; 51(7): 719–727. doi: 10.1111/apt.15665.

23. Diaz LI, Keihanian T, Schwartz I et al. Vedolizumab-induced de novo extraintestinal manifestations. Gastroenterol Hepatol 2020; 16(2): 75–81.

24. de Krijger M, Buskens CJ, Wildenberg ME et al. T cells expressing integrin α4β7 are abundant in fistula tracts of Crohn’s disease patients. J Crohn Colitis 2018; 12 (Suppl 1): S114. doi: 10.1093/ecco-jcc/jjx180.171.

25. Lakatos PL, Lakatos L, Kiss LS et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion 2012; 86 (Suppl 1): S28–S35. doi: 10.1159/000341950.

26. Tadbiri S, Peyrin-Biroulet L, Serrero M et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther 2018; 47(4): 485–493. doi: 10.1111/apt.14419.

27. Cohen RD, Bhayat F, Blake A et al. The safety profile of vedolizumab in ulcerative colitis and Crohn’s disease: 4 years of global post-marketing data. J Crohns Colitis 2020; 14(2): 192–204. doi: 10.1093/ecco-jcc/jjz137.

28. Card T, Ungaro R, Bhayat F et al. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment Pharmacol Ther 2020; 51(1): 149–157. doi: 10.1111/apt.15538.

29. Engel T, Ungar B, Yung DE et al. Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis 2018; 12(2): 245–257. doi: 10.1093/ecco-jcc/jjx143.